Opinion

Video

Care Coordination for High-Risk CRM Patients

Key Takeaways

  • Future guidelines may integrate emerging evidence and novel therapeutic strategies for CKD, T2D, and CVD management.
  • Personalized treatment plans considering the interplay between CKD, T2D, and CVD could be emphasized.
SHOW MORE

Medical experts examine strategies for care coordination in high-risk patients with cardiometabolic conditions.

Video content above is prompted by the following:

  • How do you define effective care coordination in the context of high-risk CRM patients?
  • What are the key elements of a successful care coordination program for these patients?
  • Why is this so challenging at the large health systems represented here and around the country?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo